We are proud to announce that a groundbreaking project led by our esteemed faculty member, Assoc. Prof. Dr. Ali Kılıç, has been selected for funding by the Presidency of Turkish Health Institutes (TÜSEB).
We are proud to announce that a groundbreaking project led by our esteemed faculty member, Assoc. Prof. Dr. Ali Kılıç, has been selected for funding by the Presidency of Turkish Health Institutes (TÜSEB). Initiated this year, the project focuses on innovative approaches to tackle type 2 diabetes and its severe complication, diabetic foot ulcers.
Type 2 diabetes and diabetic foot ulcers significantly impact patients' quality of life, often leading to amputations and increased mortality rates. Furthermore, the prevalence of these conditions is expected to rise substantially in the next 20 years. Addressing this growing health crisis, the project aims to develop two advanced wound dressing formulations to provide effective and long-lasting treatment solutions.
Specifically, the research involves the formulation of PLA/hyaluronic acid and PLA/heparin-based wound dressings, combined with an anti-inflammatory drug encapsulated in liposomal nanoparticles. Using a proprietary bionanofiber gun, these formulations will be applied to a collector to produce the wound dressings.
The produced wound dressings will undergo comprehensive testing, including assessments of cellular toxicity, growth parameters, and their effects on molecules related to inflammation and hyperglycemia in fibroblast and keratinocyte cell lines. These tests will be conducted in a 3D in vitro culture system that includes cocultured immune system cells, followed by in vivo testing.
We congratulate Assoc. Prof. Dr. Ali Kılıç on this remarkable achievement and wish continued success in his efforts to contribute to medical science and improve the lives of individuals affected by diabetes and its complications.
